Workshops With Experts: Advances to Improve Clinical Outcomes for Veterans With Pancreatic Cancer

Join this expert-led 1-hour live workshop to learn how to select and apply optimal therapeutic strategies for veterans with newly diagnosed or relapsed/refractory pancreatic cancer.


Overview of Pancreatic Cancer

Case Discussions:

  • Optimal Treatment Approach for Newly Diagnosed Advanced Pancreatic Cancer
  • Selecting Treatment for Patients With Advanced Pancreatic Cancer Who Progress After Initial Therapy
  • Management of Adverse Events

Future Directions in Advanced Pancreatic Adenocarcinoma

Audience Question and Answer Session




Date / Time
Event Details


Goal Statement
The goal of this activity is to improve the competence and performance of learners to select and apply and optimal therapeutic strategies for veterans with newly diagnosed or relapsed/refractory pancreatic ductal adenocarcinoma.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare professionals working within the VHA system who care for patients with pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Consider efficacy and safety evidence as well as patient characteristics and preferences to individualize therapeutic strategies for patients with newly diagnosed pancreatic cancer and advanced pancreatic cancer following first-line systemic therapy based on available data and treatment guidelines (maintenance or progression)
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Appraise the rationale for available/emerging data for the use of novel chemotherapy platforms, PARP inhibitors, immunotherapy (and immunotherapy-based combinations), stroma-targeting agents, and tumor treating fields therapy (TTFields), and others for pancreatic cancer
  • Manage disease-related and treatment-related symptoms for patients with advanced pancreatic cancer
  • Identify patients suitable for enrollment on ongoing clinical studies of emerging investigational agents and treatment strategies in advanced pancreatic cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-005-L01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.